| Literature DB >> 24502508 |
Gordon J Hendry1, Debbie E Turner, Janet Gardner-Medwin, Paula K Lorgelly, James Woodburn.
Abstract
BACKGROUND: An increased awareness of patients' and parents' care preferences regarding foot care is desirable from a clinical perspective as such information may be utilised to optimise care delivery. The aim of this study was to examine parents' preferences for, and valuations of foot care and foot-related outcomes in juvenile idiopathic arthritis (JIA).Entities:
Year: 2014 PMID: 24502508 PMCID: PMC3929162 DOI: 10.1186/1757-1146-7-10
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Description of final attributes and levels in the hypothetical scenarios
| Pain relief | Following treatment you will have the following pain level | pain_0; no lower limb pain experienced whatsoever, pain_1; A noticeable improvement in lower limb pain, pain_2; no change in the levels of pain |
| Improvement in mobility | Following treatment you will have the following ability | mobility_0; Ability to move freely, mobility_1; a noticeable improvement in the ability to move but some limitations, mobility_2; No change in movement ability |
| Activities of daily living | Following treatment you will have the following ability | adl_0; Ability to take part in all usual everyday activities, adl_1; Ability to take part in some usual everyday activities, adl_2; No improvement in ability |
| Route to podiatry care (foot care) | You will receive podiatry care via | route_0; The appointment includes seeing the consultant, the podiatrist and the physiotherapist in the same visit, route_1; The consultant would decide whether to refer you/your child to the podiatrist |
| Waiting time | The waiting time for first podiatry contact will be | Wait; 3months, 6months, 1 year. |
| Footwear | Following treatment you will be able to wear | footwear_0; ability to wear |
| Cost to you | The total cost of the appointment to you will be | Cost; £80, £150, £220. |
Figure 1An extract choice set from the final DCE questionnaire. Eighteen of these choice sets were presented in the final questionnaire.
Baseline characteristics of the parent RCT[23]participants (n = 42 children/adolescents)
| Age (yrs)* | 10.1 (3.8) |
| Male/female (n) | 13/29 |
| Body mass index* | 19.1 |
| SDS BMI percentiles* | 64.5 (0.3) |
| Disease duration (months)* | 46.9 (35.9) |
| | |
| Analgesics: n (%) | 5 (12) |
| NSAIDs: n (%) | 5 (12) |
| Methotrexate: n (%) | 32 (76) |
| Etanercept: n (%) | 12 (29) |
| Sulphasalazine: n (%) | 1 (2) |
| Rituximab: n (%) | 1 (2) |
| Combination methotrexate & etanercept: n (%) | 10 (24) |
| | |
| Persistent oligo: n (%) | 10 (24) |
| Extended oligo: n (%) | 9 (21) |
| Poly-: n (%) | 15 (36) |
| Poly+: n (%) | 2 (5) |
| PsA: n (%) | 3 (7) |
| ERA: n (%) | 2 (5) |
| Systemic: n (%) | 0 (0) |
| Undifferentiated: n (%) | 1 (2) |
*Mean (standard deviation); n, number of participants; SDS, standardised deviation score British 1990 growth reference (UK 90); NSAID, non-steroidal anti-inflammatory drugs; Poly -, polyarthritis rheumatoid factor negative; poly+, polyarthritis rheumatoid factor positive; PsA, psoriatic arthritis; ERA, enthesitis related arthritis.
Frequencies (absolute and cumulative %) of observations for each attribute level
| pain_0 | 250 | 40.65 | 40.65 | |
| | pain_1 | 219 | 35.61 | 76.26 |
| | pain_2 | 146 | 23.74 | 100.00 |
| mobility_0 | 246 | 40.00 | 40.00 | |
| | mobility_1 | 222 | 36.10 | 76.10 |
| | mobility_2 | 147 | 23.90 | 100.00 |
| adl_0 | 292 | 47.48 | 47.48 | |
| | adl_1 | 187 | 30.41 | 77.89 |
| | adl_2 | 136 | 22.11 | 100.00 |
| route_0 | 345 | 56.10 | 56.10 | |
| | route_1 | 270 | 43.90 | 100.00 |
| 3 months | 229 | 37.24 | 37.24 | |
| | 6 months | 189 | 30.73 | 67.97 |
| | 12 months | 197 | 32.03 | 100.00 |
| footwear_0 | 250 | 40.65 | 40.65 | |
| | footwear_1 | 206 | 33.50 | 74.15 |
| | footwear_2 | 159 | 25.85 | 100.00 |
| £80 | 185 | 30.08 | 30.08 | |
| | £150 | 195 | 31.71 | 61.79 |
| £220 | 235 | 38.21 | 100.00 |
*pain_0; no lower limb pain; pain_1 a noticeable improvement, pain_2; no change, mobility_0; ability to move freely, mobility_1; a noticeable improvement; mobility_2; no change; adl_0 ability to take part in all activities, adl_1; ability to take part in some activities, adl_2 no improvement, route_0; appointment including the consultant, podiatrist and physio, route_1; consultant’s decision to refer, waiting time; 3months, 6months, 12months, footwear_0; ability to wear most shoes, footwear_1; ability to wear limited shoes, footwear_2; custom shoes only, cost; £80, £150, £220.
Results from the fixed effect multinomial logit regression
| pain_0 | 0.94 | 0.15 | (0.65, 1.24) | p < 0.01 |
| pain_1 | 0.75 | 0.15 | (0.47, 1.04 | p < 0.01 |
| mobility_0 | 0.89 | 0.15 | (0.61, 1.18) | p < 0.01 |
| mobility_1 | 0.69 | 0.14 | (0.41, 0.98) | p < 0.01 |
| adl_0 | 1.29 | 0.14 | (1.01, 1.58) | p < 0.01 |
| adl_1 | 0.58 | 0.15 | (0.29, 0.86) | p < 0.01 |
| Route | 0.31 | 0.09 | (0.12, 0.5) | p < 0.01 |
| Wait** | −0.04 | 0.02 | (-0.07, -0.008) | p = 0.013 |
| footwear_0 | 0.83 | 0.14 | (0.54, 1.11) | p < 0.01 |
| footwear_1 | 0.48 | 0.14 | (0.19, 0.76) | p < 0.01 |
| Cost** | 0.002 | 0.001 | (-0.0005, 0.004) | p = 0.138 NS |
*pain_0; no lower limb pain; pain_1 a noticeable improvement, mobility_0; ability to move freely, mobility_1; a noticeable improvement; adl_0 ability to take part in all activities, adl_1; ability to take part in some activities, route; appointment including the consultant, podiatrist and physio, footwear_0; ability to wear most shoes, footwear_1; ability to wear limited shoes.
**continuous variables.
Figure 2Error bars showing beta coefficients and associated 95% confidence intervals derived from fixed effects multinomial logit regression analysis.
Figure 3Comparison of the % frequency of n = 42 stated preference WTP values versus n = 615 DCE WTP observations from the same respondents.